N-desmethyl sildenafil is the major circulating pharmacologically active metabolite formed during sildenafil biotransformation. It retains a phosphodiesterase selectivity profile similar to the parent drug, although official labeling describes its in vitro potency for PDE5 as approximately 50% of parent sildenafil.
The metabolite should not be treated as if it were simply another measurement of parent sildenafil. Formation, systemic concentration, distribution and elimination create a distinct concentration-time profile that overlaps with but does not duplicate the parent-drug profile. In healthy-volunteer data described in product labeling, circulating metabolite concentrations are approximately 40% of those observed for sildenafil.
This page focuses on the identity, pharmacologic activity and exposure context of N-desmethyl sildenafil. The enzymatic steps that generate it belong on the sildenafil metabolism page, while this page follows what the active metabolite means after it has been formed.
N-desmethyl sildenafil is a metabolite produced when parent sildenafil undergoes enzymatic biotransformation. It is described in official labeling as the major circulating active metabolite, distinguishing it from downstream metabolic products that do not make the same contribution to sildenafil-related pharmacology.
Unlike an inactive breakdown product, N-desmethyl sildenafil retains pharmacologic activity. Its phosphodiesterase selectivity profile is similar to that of sildenafil, although its in vitro potency for PDE5 is approximately one-half that of the parent compound.
Within the broader sildenafil pharmacokinetic framework, N-desmethyl sildenafil is best considered a separate analyte with its own formation, systemic exposure and elimination characteristics.
| Entity | PK-PD Role |
|---|---|
| Parent sildenafil | Administered active compound. |
| N-desmethyl sildenafil | Major circulating active metabolite formed through biotransformation. |
| Downstream metabolites | Products formed through further metabolic processing. |
A metabolite is considered pharmacologically active when it retains the ability to interact with a relevant biological target after formation from the parent compound. Metabolism therefore does not always mean that drug-related pharmacologic activity ends immediately.
N-desmethyl sildenafil remains active at the PDE5 target system. Official labeling reports an in vitro PDE5 potency of approximately 50% of parent sildenafil, which means the metabolite retains meaningful activity but should not be treated as pharmacologically identical to the parent drug.
The presence of an active metabolite creates an additional layer between parent-drug pharmacokinetics and the total pharmacodynamic environment. Its relevance depends not only on intrinsic activity but also on how much metabolite is formed, how much circulates and how long that exposure persists.
| Metabolite Type | General Interpretation |
|---|---|
| Active metabolite | Retains pharmacologically relevant activity. |
| Inactive metabolite | Does not meaningfully contribute to the parent drug's principal pharmacological activity. |
| Further metabolic product | May represent an intermediate or downstream stage of elimination. |
Parent sildenafil and N-desmethyl sildenafil are chemically related but pharmacokinetically distinct entities. Parent drug must first be present and metabolized before the active metabolite can form, so the two analytes enter the systemic profile through different processes.
As a result, the metabolite concentration-time profile reflects both formation from the parent and subsequent removal of the metabolite itself. Parent sildenafil, by contrast, reflects absorption, distribution, metabolism and elimination of the originally administered compound.
The two profiles therefore overlap but should not be assumed to have identical Cmax, Tmax, AUC or elimination characteristics. They also differ in intrinsic activity: N-desmethyl sildenafil has approximately 50% of the parent drug's in vitro PDE5 potency, even though both remain pharmacologically active.
| Feature | Parent Sildenafil | N-Desmethyl Sildenafil |
|---|---|---|
| Origin | Administered parent compound | Formed metabolically from parent sildenafil |
| Systemic appearance | Depends on absorption and bioavailability | Depends on metabolite formation |
| Exposure profile | Has its own concentration-time curve | Has a separate concentration-time curve |
| Pharmacologic activity | Active | Active |
| Relative in vitro PDE5 potency | Reference parent activity | Approximately 50% of parent sildenafil |
| Plasma protein binding | Approximately 96% | Approximately 96% |
N-desmethyl sildenafil is generated through N-desmethylation during oxidative metabolism of parent sildenafil. Its appearance in plasma therefore depends first on the availability of parent drug to the relevant metabolic pathways.
Formation is only the first part of the metabolite's pharmacokinetics. Once produced, N-desmethyl sildenafil can distribute, circulate, undergo additional metabolism and eventually be eliminated, so its systemic profile cannot be inferred solely from the amount of parent drug present at one point in time.
The enzyme pathways responsible for parent-drug transformation are covered on the sildenafil metabolism page, with CYP3A4-specific mechanism discussed on the sildenafil CYP3A4 page.
| Stage | Metabolite Context |
|---|---|
| Parent-drug availability | Provides substrate for metabolite formation. |
| Biotransformation | Generates N-desmethyl sildenafil. |
| Metabolite circulation | Creates a measurable plasma concentration profile. |
| Further disposition | Includes additional metabolism and elimination. |
A metabolite concentration is determined by two competing processes: the rate at which the metabolite is formed and the rate at which it is subsequently removed. This means its measured plasma concentration reflects a dynamic balance rather than formation alone.
Metabolite pharmacokinetics are therefore more complex than assuming that the plasma profile simply follows parent sildenafil with a fixed delay. Formation can continue while N-desmethyl sildenafil is simultaneously being distributed, further metabolized and eliminated.
The resulting concentration-time profile represents the net balance between ongoing production from parent sildenafil and downstream metabolite disposition. Changes in either side of this balance can alter metabolite Cmax, AUC or the shape of its decline.
| Process | Effect on Metabolite Concentration |
|---|---|
| Formation from parent drug | Adds metabolite to the systemic pool. |
| Distribution | Moves metabolite between plasma and tissues. |
| Further metabolism | Removes or transforms circulating metabolite. |
| Elimination | Reduces metabolite amount over time. |
Because N-desmethyl sildenafil must first be formed from parent drug, its plasma concentration-time profile reflects metabolite formation as well as its own disposition. Its measured concentration at any point therefore depends on how quickly it is being generated relative to how quickly it is leaving the measured plasma compartment.
Its rise, peak and decline cannot be interpreted using the parent-drug curve alone. A metabolite can reach its maximum concentration at a different time and can show a decline influenced by continued formation even after parent sildenafil concentrations have already begun to fall.
The general principles for interpreting plasma curves are explained on the sildenafil concentration-time page, while this page applies those concepts specifically to the active metabolite.
| Curve Region | Metabolite Interpretation |
|---|---|
| Initial rise | Formation begins to exceed metabolite removal. |
| Peak | Highest observed metabolite concentration. |
| Declining phase | Net removal exceeds ongoing formation. |
| Terminal phase | Late disposition of the metabolite becomes dominant. |
Like parent sildenafil, N-desmethyl sildenafil exposure can be characterized using serial concentration measurements and pharmacokinetic parameters such as peak concentration, peak timing and integrated exposure. Each parameter refers specifically to the metabolite rather than to sildenafil as a combined parent-metabolite system.
Metabolite AUC represents the integrated circulating exposure of N-desmethyl sildenafil, while metabolite Cmax represents its own observed concentration peak. Product labeling reports that, in healthy volunteers, plasma concentrations of the active metabolite are approximately 40% of those seen for sildenafil.
That 40% figure describes the relative circulating concentration context and should not be interpreted as identical pharmacological potency. Keeping analyte-specific concentration and activity measurements separate is essential when interpreting the overall sildenafil exposure framework.
| Metric | Active-Metabolite Meaning |
|---|---|
| Metabolite Cmax | Highest observed N-desmethyl sildenafil concentration. |
| Metabolite Tmax | Time of the observed metabolite concentration peak. |
| Metabolite AUC | Integrated systemic exposure to N-desmethyl sildenafil. |
| Relative plasma concentration | Approximately 40% of sildenafil concentrations in healthy-volunteer labeling data. |
Parent sildenafil AUC and active-metabolite AUC represent exposure to two different analytes. They cannot be combined or compared as if they were the same concentration measurement because the parent is administered directly while the metabolite must first be generated through biotransformation.
A change in parent-drug exposure can influence metabolite formation, but the direction and magnitude of metabolite exposure also depend on formation efficiency and downstream metabolite disposition. In other words, the parent-to-metabolite relationship is mechanistic rather than a fixed concentration ratio under every condition.
This means a higher parent sildenafil concentration does not automatically imply that metabolite concentration changes by exactly the same proportion. The approximately 40% relative plasma concentration reported in healthy-volunteer labeling data is useful context, not a universal conversion factor for every population or pharmacokinetic condition.
| Exposure Measure | What It Represents |
|---|---|
| Parent AUC | Integrated exposure to unchanged sildenafil. |
| Metabolite AUC | Integrated exposure to N-desmethyl sildenafil. |
| Total pharmacologically active exposure | Requires consideration of parent and active-metabolite activity rather than simple concentration addition. |
N-desmethyl sildenafil retains pharmacologic activity related to the same general target pathway as parent sildenafil. Its phosphodiesterase selectivity profile is similar to that of sildenafil, and official labeling describes its in vitro potency for PDE5 as approximately 50% of the parent drug.
Active does not mean identical. In addition to having lower relative in vitro potency, the metabolite circulates at a different concentration and follows its own exposure profile. Labeling reports plasma concentrations at approximately 40% of those of sildenafil in healthy volunteers and estimates that the metabolite accounts for about 20% of sildenafil's pharmacologic effects.
The approximately 20% figure is a pharmacologic estimate derived from the combined context of relative activity and systemic presence; it should not be interpreted as a direct prediction of an individual's clinical response. The broader relationship between circulating drug concentrations and biological response belongs on the sildenafil pharmacodynamics page.
| Property | Why It Matters |
|---|---|
| PDE5 potency | Approximately 50% of parent sildenafil in vitro. |
| Systemic concentration | Approximately 40% of sildenafil concentrations in healthy-volunteer labeling data. |
| Estimated pharmacologic contribution | About 20% of sildenafil's pharmacologic effects in labeling. |
| Exposure duration | Determines how metabolite concentrations evolve across time. |
PK-PD interpretation becomes more complex when both a parent drug and an active metabolite are present because measured biological activity may reflect contributions from more than one circulating active species. Sildenafil and N-desmethyl sildenafil should therefore be tracked as separate pharmacokinetic entities before their activity is interpreted together.
Parent and metabolite concentrations can follow different time courses, and the metabolite also has lower intrinsic PDE5 potency than the parent compound. Their relative pharmacologic contribution can therefore change across the post-administration period rather than remaining fixed at every time point.
A complete PK-PD model distinguishes the concentration and intrinsic activity of each active analyte from the downstream pharmacodynamic response. The labeling estimate that N-desmethyl sildenafil contributes about 20% of sildenafil's pharmacologic effects provides useful context, but it is not itself a direct clinical-effect measurement.
| Layer | Example |
|---|---|
| Parent PK | Sildenafil concentration-time profile. |
| Metabolite PK | N-desmethyl sildenafil concentration-time profile. |
| Pharmacodynamics | Biological response associated with active exposure. |
| Clinical observation | Measured outcome influenced by the full biological context. |
Because CYP3A4 contributes substantially to sildenafil metabolism, changes in this pathway can alter the balance between parent-drug removal and metabolite formation. This creates a linked relationship in which the same metabolic pathway can influence both parent sildenafil exposure and input into the active-metabolite pool.
Reduced parent-drug metabolism can increase sildenafil exposure while also changing the rate at which metabolic products are generated. The final N-desmethyl sildenafil profile still depends on its subsequent distribution, further metabolism and removal, so parent and metabolite exposure do not necessarily change in identical proportions.
The enzyme mechanism itself is treated on the sildenafil CYP3A4 page; this page focuses on what the resulting active metabolite represents.
| Mechanistic Change | Potential PK Consequence |
|---|---|
| Altered parent metabolism | Changes parent sildenafil concentration. |
| Altered metabolite formation | Can change active-metabolite input. |
| Unchanged metabolite removal | Final metabolite exposure still depends on its downstream disposition. |
Once N-desmethyl sildenafil has been formed, it becomes subject to its own metabolic and elimination processes. Its disappearance from plasma is therefore not determined solely by the elimination of parent sildenafil.
This distinction is especially important when interpreting terminal concentration behavior. Parent and metabolite are separate circulating chemical entities, and the metabolite's observed decline reflects both ongoing input from parent-drug metabolism and its own downstream removal.
The general removal-efficiency concept is covered on the sildenafil clearance page, although metabolite-specific disposition should be interpreted separately from parent-drug clearance.
| Process | Parent Sildenafil | Active Metabolite |
|---|---|---|
| Systemic appearance | Primarily follows absorption | Primarily follows metabolic formation |
| Removal | Parent-drug clearance | Metabolite-specific disposition |
| Terminal decline | Reflects parent PK | Reflects formation history plus metabolite elimination |
Half-life belongs to a specific analyte and concentration-time profile, so parent and metabolite half-life should conceptually remain separate parameters. That distinction remains important even when their reported numerical values happen to be similar.
Official labeling reports terminal half-lives of about 4 hours for both sildenafil and its active N-desmethyl metabolite. For the metabolite, however, the observed decline still reflects its own removal together with any continuing formation from parent drug, so a similar numerical half-life does not make the two concentration-time profiles interchangeable.
The general meaning of elimination half-life is explained on the sildenafil half-life page.
| Parameter | Interpretation |
|---|---|
| Parent half-life | Terminal half-life of about 4 hours in labeling. |
| Metabolite half-life | Terminal half-life of about 4 hours in labeling. |
| Formation rate | Can influence the apparent metabolite concentration-time profile. |
N-desmethyl sildenafil exposure can vary because metabolite concentrations depend on several processes: parent-drug exposure, metabolic formation, metabolite distribution and subsequent removal. Variation at any of these stages can alter the observed parent-to-metabolite relationship.
Differences in metabolic enzyme activity can affect both sides of that relationship. A factor that changes sildenafil metabolism may increase or decrease parent exposure while simultaneously altering the rate at which N-desmethyl sildenafil is generated.
The approximately 40% metabolite-to-parent plasma concentration relationship reported in healthy volunteers should therefore be interpreted as study and labeling context rather than as a fixed ratio in every population. These mechanisms form part of the broader sildenafil pharmacokinetic variability framework.
| Source of Variation | Potential Metabolite Effect |
|---|---|
| Parent-drug exposure | Changes substrate available for metabolite formation. |
| Metabolic activity | Changes formation rate. |
| Metabolite distribution | Changes plasma-to-tissue relationships. |
| Metabolite removal | Changes persistence of circulating metabolite. |
The presence of an active metabolite establishes pharmacological relevance but does not make metabolite plasma concentration a direct measure of clinical outcome. Concentration describes systemic exposure, while clinical response requires a separate pharmacodynamic and physiological interpretation.
Observed effect depends on the combined PK-PD relationship involving parent sildenafil, active metabolite, target interaction and downstream biological factors. The metabolite's approximately 50% relative in vitro PDE5 potency and the labeling estimate of about 20% pharmacologic contribution help characterize its relevance without turning concentration into a direct response measure.
For this reason, metabolite exposure should be described as part of the pharmacologic context rather than converted into predictions about the magnitude, timing or duration of an individual's response.
| Observation | What It Establishes |
|---|---|
| Metabolite detected in plasma | The metabolite is systemically present. |
| Metabolite is pharmacologically active | It can contribute to the relevant biological pathway. |
| Higher metabolite exposure | More integrated metabolite exposure is present. |
| Specific clinical response | Requires separate pharmacodynamic and clinical interpretation. |
N-desmethyl sildenafil is best understood as a separate active pharmacokinetic entity generated from parent sildenafil. Its importance comes from the combination of measurable systemic exposure and retained PDE5 activity rather than from either concentration or potency considered alone.
Official labeling provides useful reference points: the metabolite has approximately 50% of parent sildenafil's in vitro PDE5 potency, plasma concentrations are approximately 40% of parent concentrations in healthy volunteers, and its pharmacologic contribution is estimated at about 20%. Both parent sildenafil and N-desmethyl sildenafil are also approximately 96% protein bound and have reported terminal half-lives of about 4 hours.
These values help define the parent-metabolite relationship but do not make their pharmacokinetic profiles interchangeable. For the broader pathway, the sildenafil pharmacokinetics hub connects active-metabolite exposure with metabolism, CYP3A4 activity, clearance and systemic exposure.
| Research Question | Relevant Concept |
|---|---|
| What is the major active sildenafil metabolite? | N-desmethyl sildenafil |
| How is it generated? | Parent-drug metabolism |
| Does it have its own plasma profile? | Yes; metabolite concentration-time exposure |
| Can it contribute pharmacologic activity? | Yes |
| Is its exposure identical to parent exposure? | No |
N-desmethyl sildenafil is the major circulating active metabolite formed during the enzymatic metabolism of parent sildenafil.
Yes. N-desmethyl sildenafil retains a phosphodiesterase selectivity profile similar to sildenafil and has approximately 50% of the parent drug's in vitro potency for PDE5.
No. It is a metabolite formed from sildenafil. The parent drug and metabolite are related but distinct chemical and pharmacokinetic entities with separate concentration-time profiles.
Yes. Its plasma profile reflects both formation from parent sildenafil and the metabolite's own distribution, further metabolism and elimination. Product labeling reports metabolite plasma concentrations at approximately 40% of sildenafil concentrations in healthy volunteers.
No. Parent and metabolite AUC, Cmax and other PK measurements refer to different analytes and should be interpreted separately even though the two profiles are mechanistically connected.
Not by itself. Labeling estimates that N-desmethyl sildenafil contributes about 20% of sildenafil's pharmacologic effects, but clinical response reflects the combined parent-drug, metabolite, pharmacodynamic and physiological context.